Cognitive Disorder

People with dementia were three times more likely to have a registered care partner actively engaging with a patient portal than those without dementia, according to research published in JAMA Internal Medicine.

SAN DIEGO — Limited assessment tools make it difficult to determine the prevalence and severity of cognitive disorders in patients with rheumatic and autoimmune diseases, according to a speaker at the Congress of Clinical Rheumatology West.

Alzheon Inc. reported statistically significant and clinically relevant results in patients with Alzheimer’s disease following 12 months of treatment with the oral investigational therapeutic ALZ-801 in its phase 2 trial.

Cedars-Sinai’s department of computational biomedicine has been awarded an $8 million NIH grant to use artificial intelligence methods to identify genetic predictors of Alzheimer's disease.

Older adults with dementia are at greater risk for SARS-CoV-2 infection and death, highlighting the need for close monitoring of these patients, researchers reported in the Journal for Alzheimer’s Disease.

Sage Therapeutics Inc. announced positive results from a phase 2 trial for an oral treatment that was linked to improvements in functioning, learning and memory in those with mild cognitive impairment from Parkinson’s disease.

Healio Neurology’s most-viewed stories from 2021 highlight developments surrounding Aduhelm, the benefits of flavonoid on cognitive function and neurologic symptoms in COVID-19.

Identifying and addressing risk factors for cognitive disorders shared within couples may reduce the risk for these disorders in the spouses of those with dementia, according to results of a prospective cohort study in JAMA Network Open.

Patients with Alzheimer’s disease who use antipsychotic medications may be at an increased risk for head injuries and traumatic brain injuries, or TBIs, according to findings of a nationwide register-based cohort study conducted in Finland and published in Journal of the American Geriatrics Society.